Keywords (1)

Academic
Publications
PARP inhibitors for cancer therapy

PARP inhibitors for cancer therapy,10.1017/S146239940500904X,Expert Reviews in Molecular Medicine,Nicola J. Curtin

PARP inhibitors for cancer therapy   (Citations: 47)
BibTex | RIS | RefWorks Download
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ...Several PARP inhibitors are currently undergoing clinical evaluation [9,10], and a toxic effect against non proliferating cells was hypothesized [11]...

    Riccardo Caldiniet al. Low doses of 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor...

    • ...For instance, Banasik and colleagues [76] identified a number of more potent inhibitors including 1,5-dihydroisoquinoline, 2-methyquinazolin-4-(3H)-one, 4-amino-1-8-napthalimide and 2-nitro-6-(5H)-phenanthridinone, which have been used as lead compounds for subsequent drug development and the identification of the essential features for efficient PARP inhibition through structure‐activity studies (see [77])...

    Frédérique Mégnin-Chanetet al. Targeting poly(ADP-ribose) polymerase activity for cancer therapy

    • ...Now, concerning the role of PARP inhibition involved in the potentiation of radiation (e.g ionizing radiation) and cytotoxic chemotherapeutic agents such as DNA alkylating agents (temezolomide and cyclophosphamide); platinium analogues (cisplatin, carboplatin and oxaliplatin); and topoisomerase I poisons (irinotecan and 9-topotecan) [2, 84]...
    • ...Others—NU1025 enhanced cytotoxicity of DNA methylating agents and ionizing radiation by inhibiting DNA repair and further showed that PARP inhibitors may be potentially useful in combination with topoisomerase I inhibitor in anticancer chemotherapy [84]...

    Nilufer Jasmine Selimah Fauzeeet al. PARP and PARG Inhibitors—New Therapeutic Targets in Cancer Treatment

    • ...Inhibition, or lack, of PARP-1 results in hyper-sensitivity to DNA methylating agents, topoisomerase I poisons and ionising radiation, all used in the treatment of cancer [6]...

    Tomasz Zarembaet al. Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP...

    • ...Poly (ADP-ribose) polymerase (PARP) is an enzyme involved in the regulation of DNA damage repair [35] (Fig. 1). PARP inhibition leads to unrepaired single-strand breaks, which are normally repaired by the homologous recombination double-stranded DNA repair pathway, whose key components include the BRCA1 and BRCA2 proteins that are commonly mutated in cancer [35, 36]...
    • ...PARP inhibitors work by disabling the base-excision repair mechanism in cells with mutant BRCA1 or BRAC2 proteins with defects in homologous recombination; these cells, as opposed to those harboring wild-type BRCA1 or BRCA2, are unable to repair DNA and consequently die, a paradigm known as synthetic lethality [35]...

    Luai Zarouret al. Emerging Therapies in Castrate-Resistant Prostate Cancer

Sort by: